News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

New Grant Enables Humanetics To Evaluate Potential Treatment For Erectile Dysfunction In Prostate Cancer Patients


7/9/2014 1:55:31 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MINNEAPOLIS--(BUSINESS WIRE)--Minneapolis-based Humanetics Corporation (Humanetics) has been awarded a grant from the National Cancer Institute (NCI) to evaluate their proprietary radioprotectant compound, BIO 300, as a potential treatment for erectile dysfunction (ED) following prostate cancer radiotherapy. Research will be conducted in collaboration with Dr. Zeljko Vujaskovic, Director of the Division of Translational Radiation Sciences at the University of Maryland School of Medicine.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES